84,519 results match your criteria Lymphoma B-Cell

Scutellarin ameliorates colitis-associated colorectal cancer by suppressing Wnt/β-catenin signaling cascade.

Eur J Pharmacol 2021 Jun 9:174253. Epub 2021 Jun 9.

State Key Laboratory of Southwestern Chinese Medicine Resources, Department of Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Electronic address:

Dysregulated Wnt/β-catenin signaling pathway plays a critical role in the pathogenesis of colorectal cancer (CRC). Scutellarin, a flavonoid compound in Scutellaria barbata, has been reported to suppress CRC, with the action mechanism elusive. In this study, Scutellarin was found to inhibit the carcinogenesis of colitis-associated cancer (CAC) in mice caused by azoxymethane/dextran sulfate sodium, with alleviation of pathologic symptoms. Read More

View Article and Full-Text PDF

Primary mediastinal large B-cell lymphoma chemotherapy: Impact of chemotherapy choice.

Hematol Oncol Stem Cell Ther 2021 Jun 6. Epub 2021 Jun 6.

Department of Hematology, Kuwait Cancer Control Center, Kuwait. Electronic address:

Objective/background: Data generated from retrospective studies on primary mediastinal B-cell lymphoma (PMBCL) outcome are valuable as no prospective phase 3 trials have been conducted in this rare type of lymphoma.

Methods: Our goal was to assess the long-term outcome of 41 patients with PMBCL who were treated at the Kuwait Cancer Center. We evaluated two types of multidrug treatment, R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone) and DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), and determined overall survival and complete response (CR) as primary endpoints. Read More

View Article and Full-Text PDF

How I Diagnose Angioimmunoblastic T-Cell Lymphoma.

Am J Clin Pathol 2021 Jun 12. Epub 2021 Jun 12.

Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Objectives: Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma derived from T-follicular helper cells. For pathologists, diagnosing AITL may be challenging due to its wide clinical and histopathologic spectrum, which can mimic a variety of reactive and neoplastic processes.

Methods: We summarize and discuss the clinicopathologic features of AITL, emphasizing diagnostic tools available to the practicing pathologist. Read More

View Article and Full-Text PDF

Exercise attenuates angiotensinⅡ-induced muscle atrophy by targeting PPARγ/miR-29b.

J Sport Health Sci 2021 Jun 8. Epub 2021 Jun 8.

Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, School of Life Science, Shanghai University, Shanghai 200444, China; Shanghai Engineering Research Center of Organ Repair, School of Medicine, Shanghai University, Shanghai 200444, China. Electronic address:

Background: Exercise is beneficial for muscle atrophy. Peroxisome proliferator-activated receptor gamma (PPARγ) and microRNA-29b (miR-29b) have been reported to be responsible for angiotensin Ⅱ (AngⅡ)-induced muscle atrophy. However, it is unclear whether exercise can protect AngⅡ-induced muscle atrophy by targeting PPARγ/miR-29b. Read More

View Article and Full-Text PDF

Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells.

Prostaglandins Other Lipid Mediat 2021 Jun 8:106575. Epub 2021 Jun 8.

Department of Medicine Solna, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden. Electronic address:

Human B-lymphocytes express 5-lipoxygenase (5-LOX) and 5-LOX activating protein (FLAP) and can convert arachidonic acid to leukotriene B. Mantle cell lymphoma (MCL) cells contain similar amounts of 5-LOX as human neutrophils but the function and mechanism of activation of 5-LOX in MCL cells, and in normal B-lymphocytes, are unclear. Here we show that the intrinsic 5-LOX pathway in the MCL cell line JeKo-1 has an essential role in migration and adherence of the cells, which are important pathophysiological characteristics of B-cell lymphoma. Read More

View Article and Full-Text PDF

Spiraeoside extracted from red onion skin ameliorates apoptosis and exerts potent antitumor, antioxidant and enzyme inhibitory effects.

Food Chem Toxicol 2021 Jun 8;154:112327. Epub 2021 Jun 8.

Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul 05029, Republic of Korea. Electronic address:

Red onion skin waste (ROSW) was analyzed for extraction of naturally occurring 4'-O-glucoside of quercetin, spiraeoside (SPI) with promising biological activities. Reversed-phase high-performance liquid chromatography was used to determine the SPI content in three different solvent extracts of ROSW: water (12.2 mg/g), methanol (27. Read More

View Article and Full-Text PDF

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.

Clin Nucl Med 2021 Jun 10. Epub 2021 Jun 10.

From the Department of Haematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite Claude Bernard Lyon 1 University, Lyon Departments of Nuclear Medicine Critical Care Pharmacy Haematology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite INSERM U1052 and CNRS UMR5286, Lyon Cancer Research Center, Lyon Department of Biology and Therapy, Etablissement Français du Sang Auvergne-Rhône-Alpes Department of Haematology, Grenoble University Hospital, Grenoble Department of Haematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne Department of Haematology, Centre Léon Bérard, Lyon Department of Haematology, Groupe Hospitalier Mutualiste, Institut Daniel Hollard, Grenoble Department of Haematology, Clermont Ferrand University Hospital, Clermont Ferrand, France.

Purpose Of The Report: We aimed to evaluate the role of 18F-FDG PET/CT in predicting patient outcome following chimeric antigen receptor T (CAR T) cells infusion in aggressive B-cell lymphoma.

Methods: 18F-FDG PET/CT data before leukapheresis, before CAR T-cell infusion and 1 month (M1) after CAR T-cell infusion, from 72 patients were retrospectively analyzed. SUVmax, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and parameters describing tumor kinetics were calculated for each 18F-FDG PET/CT performed. Read More

View Article and Full-Text PDF

Venetoclax for the Treatment of Multiple Myeloma: Outcomes Outside of Clinical Trials.

Am J Hematol 2021 Jun 11. Epub 2021 Jun 11.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester.

Introduction: Multiple myeloma (MM) remains an incurable disease despite incorporation of novel agents. Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor is approved for some hematologic malignancies but not yet for MM, although clinical trials have shown efficacy in patients with MM particularly those harboring t(11;14).

Methods: We reviewed the medical records of relapsed and/or refractory MM patients to study the efficacy and safety of venetoclax used outside of clinical trials at Mayo Clinic between December 2016 and March 2019. Read More

View Article and Full-Text PDF

Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.

Leuk Lymphoma 2021 Jun 11:1-14. Epub 2021 Jun 11.

Department of Medicine, Section of Hematology, South Älvsborg Hospital, Borås, Sweden.

The complexity of the activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) subtype is probably not only explained by genetic alterations and methods to measure global protein expression could bring new knowledge regarding the pathophysiology. We used quantitative proteomics to analyze the global protein expression of formalin-fixed paraffin-embedded (FFPE) tumor tissues from 202 DLBCL patients. We identified 6430 proteins and 498 were significantly regulated between the germinal center B-cell like (GCB) and non-GCB groups. Read More

View Article and Full-Text PDF

Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience.

J Cachexia Sarcopenia Muscle 2021 Jun 11. Epub 2021 Jun 11.

Division of Hematology, ASST Spedali Civili, Brescia, Italy.

Background: Elderly classical Hodgkin lymphoma (cHL) (ecHL) is a rare disease with dismal prognosis and no standard treatment. Fitness-based approaches may help design appropriate treatments. Sarcopenia has been associated with an increased risk of treatment-related toxicities and worse survival in various solid tumours, but its impact in ecHL is unknown. Read More

View Article and Full-Text PDF

Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma.

J Cell Mol Med 2021 Jun 11. Epub 2021 Jun 11.

Department of Physiology, McGill University, Montreal, QC, Canada.

MYSM1 is a chromatin-binding protein, widely investigated for its functions in haematopoiesis in human and mouse; however, its role in haematologic malignancies remains unexplored. Here, we investigate the cross-talk between MYSM1 and oncogenic cMYC in the transcriptional regulation of genes encoding ribosomal proteins, and the implications of these mechanisms for cMYC-driven carcinogenesis. We demonstrate that in cMYC-driven B cell lymphoma in mouse models, MYSM1-loss represses ribosomal protein gene expression and protein synthesis. Read More

View Article and Full-Text PDF

The pathologic diagnosis of mantle cell lymphoma.

Histol Histopathol 2021 Jun 11:18351. Epub 2021 Jun 11.

Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma usually characterized by t(11;14) (q13;q32), or CCND1 translocation and Cyclin D1 over expression. A very small subset of MCL may lack the t(11;14) (q13;q32) translocation and Cyclin D1 over expression, but show alternative translocations involving CCND2 and CCND3, and over expression of SOX11. In general, MCL has been considered a very aggressive and incurable lymphoma and patients with MCL usually have a poor prognosis. Read More

View Article and Full-Text PDF

Dihydromyricetin promotes apoptosis, suppresses proliferation and tumor necrosis factor-α-mediated nuclear factor kappa-B activation in nasopharyngeal carcinoma CNE-2 cell.

J Tradit Chin Med 2021 Jun;41(3):367-375

Department of Otolaryngology of the Affiliated Hospital of Guangdong Medical University, Zhanjiang 524023, China.

Objective: To investigate the efficacy of dihydromyricetin (DMY) on nasopharyngeal carcinoma (NPC) cell proliferation, apoptosis and to reveal the underlying mechanism in vitro experiments.

Methods: The CNE-2 cell line was treated with different concentrations of DMY and the effects of DMY on cell viability and proliferation were evaluated using cell counting kit-8 (CCK-8) assay and plate colony formation assay. Cellular apoptosis was detected by flow cytometry following Annexin V fluorescein isothiocyanate/propidine iodide staining. Read More

View Article and Full-Text PDF

Mitochondria-targeted cyclometalated rhodium(III) complexes: synthesis, characterization and anticancer research.

Dalton Trans 2021 Jun 11. Epub 2021 Jun 11.

School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Education Mega Centre, No. 280, Waihuandong Road, Guangzhou 510006, P.R. China.

Over the past few decades, the landscape of inorganic medicinal chemistry has been dominated by investigations on platinum or ruthenium, while the research based on other metal centers such as rhodium has been relatively insufficient. In this work, a series of cyclometalated rhodium(iii) complexes with imidazo[4,5-f][1,10]phenanthroline containing different aromatic rings were synthesized and characterized. Notably, all the complexes displayed stronger anticancer activity against various cancer cells compared with cisplatin. Read More

View Article and Full-Text PDF

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Front Oncol 2021 25;11:664421. Epub 2021 May 25.

Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Background: The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge to overcome. Here, we report the clinical results and the pharmacokinetics of bispecific CD19/22 CAR T in patients with R/R B-NHL. Read More

View Article and Full-Text PDF

Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.

Front Immunol 2021 25;12:669964. Epub 2021 May 25.

UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.

These last 20 years, research on immune tumor microenvironment led to identify some critical recurrent mechanisms used in cancer to escape immune response. Through immune checkpoints, which are cell surface molecules involved in the immune system control, it is now established that tumor cells are able to shutdown the immune response. Due to the complexity and heterogeneity of Non Hodgkin B-cell Lymphomas (NHBLs), it is difficult to understand the precise mechanisms of immune escape and to explain the mitigated effect of immune checkpoints blockade for their treatment. Read More

View Article and Full-Text PDF

-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.

Front Immunol 2021 25;12:599493. Epub 2021 May 25.

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

MYC/BCL2/BCL6 triple-hit lymphoma (THL) is an uncommon subset of high-grade B-cell lymphoma with aggressive clinical behavior and poor prognosis. TP53 mutation is an independently poor progonistic indicator in patients with THL, hence novel therapeutic strategies are needed for these patients. CD19-directed chimeric antigen receptor(CAR19)-T cell therapy has shown promising efficacy for relapsed/refractory diffuse large B cell lymphoma (RR DLBCL), but the majority of CAR19-T cell products to date have been manufactured using viral vectors. Read More

View Article and Full-Text PDF

Use of rituximab in paediatric nephrology.

Arch Dis Child 2021 Jun 10. Epub 2021 Jun 10.

Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

Rituximab is a chimeric monoclonal antibody capable of depleting B cell populations by targeting the CD20 antigen expressed on the cell surface. Its use in oncology, initially in B cell lymphoma and post-transplant lymphoproliferative disorders, predates its current utility in various fields of medicine wherein it has become one of the safest and most effective antibody-based therapies. It was subsequently found to be effective for rheumatological conditions such as rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculitis. Read More

View Article and Full-Text PDF

Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome.

Biomark Res 2021 Jun 10;9(1):46. Epub 2021 Jun 10.

Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, Jinan University, 510632, Guangzhou, PR China.

Myelodysplastic syndrome (MDS) is an aggressive and genetically heterogeneous disease with poor prognosis. Cellular immune disorder is a common characteristic of this disease and is thought to be related to clinical outcome. Alterations in T cell clonal expansion and T cell dysfunction has been detected in MDS patients. Read More

View Article and Full-Text PDF

The regulation of miR-320a/XBP1 axis through LINC00963 for endoplasmic reticulum stress and autophagy in diffuse large B-cell lymphoma.

Cancer Cell Int 2021 Jun 10;21(1):305. Epub 2021 Jun 10.

School of Basic Medicine, Jiamusi University, Jiamusi, 154007, Heilongjiang, China.

Background: This study incorporates fundamental research referring to considerable amounts of gene-sequencing data and bioinformatics tools to analyze the pathological mechanisms of diffuse large B-cell lymphoma (DLBCL).

Methods: A lncRNA-miRNA-mRNA ceRNA network of DLBCL was constructed through database analysis combining GTEx and TCGA. qPCR was used to detect the expression of LINC00963 and miR-320a in DLBCL cell lines. Read More

View Article and Full-Text PDF

Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report.

J Clin Pharm Ther 2021 Jun 10. Epub 2021 Jun 10.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

What Is Known And Objective: Treatment for diffuse large B-cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug-drug interactions, toxic effects and ART resistance must be considered.

Case Description: A 40-year-old man with drug-resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. Read More

View Article and Full-Text PDF

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.

Biosci Rep 2021 Jun 10. Epub 2021 Jun 10.

Anhui Provincial Hospital, Hefei, China.

Background: Diffuse large B-cell lymphoma used to be defined as germinal center B-like and non-germinal center B-like subtypes, associated with different prognoses, but the conventional classification does not meet the needs of clinical practice because of diffuse large B-cell lymphoma heterogeneity, a problem that might be improved by selection of miRNAs as biomarkers.

Methods: Twelve patients with diffuse large B-cell lymphomas were used to screen out the aberrant miRNA profile using miRNA microarray technology in 2 patient subtypes (6 germinal center B-like and 6 non-germinal center B-like patients). The potential biomarkers were further analyzed using the quantitative reverse transcription-polymerase chain reaction method in 95 diffuse large B-cell lymphoma patients to investigate relationships between expression levels of potent miRNA, clinicopathological features, and survival rates of patients. Read More

View Article and Full-Text PDF

Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.

Br J Haematol 2021 Jun 9. Epub 2021 Jun 9.

Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala University Hospital, Uppsala, Sweden.

Splenic marginal zone lymphoma (SMZL) is a rare low-grade B-cell lymphoma where associations with viral hepatitis and autoimmune and inflammatory diseases (AID) have been indicated. We aimed at assessing the prevalence of viral hepatitis and AID at SMZL diagnosis and outcome by treatment in a Swedish population-based study. A total of 277 SMZL patients registered in the Swedish Lymphoma Register in 2007-2017 were included. Read More

View Article and Full-Text PDF

[Molecular classification of aggressive B-cell lymphoma].

Daisuke Ennishi

Rinsho Ketsueki 2021 ;62(5):418-423

Center for Comprehensive Genomic Medicine, Okayama University Hospital.

Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically highly heterogeneous disease; various molecular genetic abnormalities contribute to DLBCL development. In particular, recent advances in genomics technologies have led to the discovery of unknown genetic abnormalities and gene expression patterns. Based on the identified pathophysiologies, molecular sub-classification of DLBCL has been progressing. Read More

View Article and Full-Text PDF

[Development and prospects of molecular targeted agents for malignant lymphoma].

Wataru Munakata

Rinsho Ketsueki 2021 ;62(5):398-406

Department of Hematology, National Cancer Center Hospital.

It has been 20 years since the clinical introduction of rituximab, a monoclonal anti-CD20 antibody. Rituximab combination chemotherapy has substantially improved the prognosis of nearly all B-cell malignancies. Twenty years following the clinical introduction of rituximab, the era of molecular targeted agents and development of novel molecular targeted agents, including monoclonal antibody based on the molecular pathology, has been promoted. Read More

View Article and Full-Text PDF

[Primary breast diffuse large B-cell lymphoma in an elderly man maintaining long-term complete response].

Rinsho Ketsueki 2021 ;62(5):341-345

Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine.

Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare non-Hodgkin's lymphoma that mostly affects women. Here, we report a case of primary breast DLBCL that affected an older man without any autoimmune disease or drug-related female hormones. The patient was a 65-year-old man whose chief complaints were gradually-increasing lump in the right chest and swelling of the right axillary lymph nodes. Read More

View Article and Full-Text PDF

circRPS28 (hsa_circ_0049055) is a novel contributor for papillary thyroid carcinoma by regulating cell growth and motility via functioning as ceRNA for miR-345-5p to regulate frizzled family receptor 8 (FZD8).

Endocr J 2021 Jun 10. Epub 2021 Jun 10.

Department of Endocrinology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, 450007, China.

Circular RNA 40S ribosomal protein S28 (circRPS28; hsa_circ_0049055) is upregulated in papillary thyroid carcinoma (PTC) patients. However, its role remained uncovered in the progression of PTC. Above all, expression of circRPS28 was determined in PTC samples by real-time quantitative PCR and circRPS28 was highly expressed in tumor tissues and cells. Read More

View Article and Full-Text PDF

1,3-Butadiene, styrene and lymphohaematopoietic cancers among North American synthetic rubber polymer workers: exposure-response analyses.

Occup Environ Med 2021 Jun 9. Epub 2021 Jun 9.

Epidemiology, The University of Alabama at Birmingham School of Public Health, Birmingham, Alabama, USA.

Objective: To evaluate exposure-response between 1,3-butadiene, styrene and lymphohaematopoietic cancers in an updated cohort of workers at six North American plants that made synthetic rubber polymers.

Methods: Employees were followed from 1943 through 2009 to determine mortality outcomes. Cox regression analyses estimated rate ratios (RRs) and 95% CIs by quartile of cumulative exposure to butadiene or styrene, measured in parts per million-years (ppm-years), and exposure-response trends for all leukaemia, lymphoid leukaemia, myeloid leukaemia, acute myeloid leukaemia, non-Hodgkin's lymphoma (NHL), multiple myeloma and all B-cell malignancies. Read More

View Article and Full-Text PDF

Raloxifene retards the progression of adjacent segmental intervertebral disc degeneration by inhibiting apoptosis of nucleus pulposus in ovariectomized rats.

J Orthop Surg Res 2021 Jun 9;16(1):368. Epub 2021 Jun 9.

Department of Orthopedic Surgery, Hebei Medical University, 361 Zhongshan E Rd, Shijiazhuang, Hebei, 050000, People's Republic of China.

Background: Adjacent segmental intervertebral disk degeneration (ASDD) is a major complication secondary to lumbar fusion. Although ASSD pathogenesis remains unclear, the primary cause of intervertebral disk degeneration (IVDD) development is apoptosis of nucleus pulposus (NP). Raloxifene (RAL) could delay ASDD by inhibiting NP apoptosis. Read More

View Article and Full-Text PDF

Diffuse Large B-Cell Lymphoma. Reply.

N Engl J Med 2021 06;384(23):2262

Memorial Sloan Kettering Cancer Center, New York, NY.

View Article and Full-Text PDF